Journal of Global Infectious DiseasesOfficial Publishing of INDUSEM and OPUS 12 Foundation, Inc. Users online:221  
Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size     
Home About us Editors Ahead of Print Current Issue Archives Search Instructions Subscribe Advertise Login 

   Table of Contents     
Year : 2011  |  Volume : 3  |  Issue : 1  |  Page : 73-78
Fundamentals of vaccine immunology

Department of Global Health, College of Public Health, University of South Florida, Tampa, FL, USA

Click here for correspondence address and email

Date of Web Publication4-Mar-2011


From a literature review of the current literature, this article provides an introduction to vaccine immunology including a primer on the components of the immune system, passive vs. active immunization, the mechanism(s) by which immunizations stimulate(s) immunity, and the types of vaccines available. Both the innate and adaptive immune subsystems are necessary to provide an effective immune response to an immunization. Further, effective immunizations must induce long-term stimulation of both the humoral and cell-mediated arms of the adaptive system by the production of effector cells and memory cells. At least seven different types of vaccines are currently in use or in development that produce this effective immunity and have contributed greatly to the prevention of infectious disease around the world.

Keywords: Adaptive immunity, Immune system, Immunization, Vaccines

How to cite this article:
Clem AS. Fundamentals of vaccine immunology. J Global Infect Dis 2011;3:73-8

How to cite this URL:
Clem AS. Fundamentals of vaccine immunology. J Global Infect Dis [serial online] 2011 [cited 2022 Sep 26];3:73-8. Available from:

   Introduction Top

As early as the fifteenth century, both the Chinese and the Turks were attempting to induce immunity to smallpox using dried crusts from smallpox lesions by either inhaling the crushed lesions or inserting them into small cuts. These initial crude attempts at immunization led to further experimentation with immunization by Lady Mary Wortley Montagu in 1718 and Edward Jenner in 1798. Edward Jenner's experiments with cowpox to stimulate smallpox immunity are better known than these earlier attempts at immunization. [1]

These early endeavors have led to the plethora of vaccines that are available today. Although these attempts were successful in providing immunity, the underlying processes required to produce this immunity were unknown.

From a literature review of the current literature, this article will provide an introduction to vaccine immunology including a primer on the components of the immune system, passive vs. active immunization, the mechanism(s) by which immunizations stimulate(s) immunity, and the types of vaccines available.

   Components of the Immune System Top

The immune system can be divided into two main subsystems, the innate/general resistance system and the adaptive system. Both the innate system and the adaptive system continually interact with each other to provide an effective immune response.

The innate immune system or general resistance includes a variety of protective measures which are continually functioning and provides a first-line of defense against pathogenic agents. However, these responses are not specific to a particular pathogenic agent. Instead, the innate immune cells are specific for conserved molecular patterns found on all microorganisms. This prevents the innate immune system from inadvertently recognizing host cells and attacking them. However, this prevents the innate immune responses from improving their reactions with repeated exposure to the same pathogenic agent. In other words, the innate immune system does not have memory.

The protective defenses of the innate immune system begin with the anatomic barriers such as intact skin and mucous membranes which prevent the entrance of many microorganisms and toxic agents. The skin also has an acidic environment of pH 3-5 which retards the growth of microorganisms. In addition, the normal microorganisms or flora, which inhabit the skin and mucous membranes compete with other microorganisms for nutrients and attachment sites. Further, the mucus and cilia on the mucous membranes aid in trapping microorganisms and propelling them out of the body. [1]

Next, the innate immune system includes such physiologic barriers as the normal body temperature, fever, gastric acidity, lysozyme, interferon, and collectins. The normal body temperature range inhibits a variety of microorganisms; and, the development of a fever can further inhibit many of these pathogenic organisms. The gastric acidity of the stomach is also quite effective in eliminating many ingested microorganisms. Lysozyme, which is a hydrolytic enzyme found in tears and mucous secretions, can cleave the peptidoglycan layer of the bacterial cell wall thus lysing the microorganism. [1] Interferon(s), which include(s) a group of proteins that are produced by virally infected cells, can bind to noninfected cells and produce a generalized antiviral state. [1] Collectins are surfactant proteins that are present in serum, lung secretions, and on mucosal surfaces. They can directly kill certain pathogenic microorganisms by disrupting their lipid membranes or indirectly by clumping microorganisms to enhance their susceptibility to phagocytosis. [1],[2]

The complement pathways are also a part of the defensive measures of the innate immune system. There are three complement pathways. The classical pathway is triggered when IgM antibodies or certain IgG antibody subclasses bind surface markers/antigens on microorganisms. The alternative or properdin pathway is triggered by the deposition of complement protein, C3b, onto microbial surfaces and does not require antibodies for activation. The third pathway, the lectin pathway, is triggered by the attachment of plasma mannose-binding lectin (MBL) to microbes and does not require antibodies for activation. These three pathways merge into a common pathway which leads to the formation of the membrane attack complex that can form pores in the membrane of targeted cells. The complement pathways are also integral in the opsonization (or increased susceptibility) of particulate antigens to phagocytosis and in triggering a localized inflammatory response. [3]

The inflammatory response is another essential part of the innate immune response. The inflammatory response is the body's reaction to invasion by an infectious agent, antigenic challenge, or any type of physical damage. The inflammatory response allows products of immune system into area of infection or damage and is characterized by the cardinal signs of redness, heat, pain, swelling, and loss of function. [1]

In addition to the anatomic and physiologic mechanisms, there are also Pattern recognition receptors or PRRs which contribute to the innate immune response. Pattern recognition receptors are not specific for any given pathogen or antigen, but can provide a rapid response to antigens. PRRs are classified as membrane proteins because they are associated with the cell membrane; and, they can be found in all the membranes of the cells in the innate immune system. Although there are several hundred varieties, all the genes of the PRRs are encoded in the germline to ensure limited variability in their molecular structures. Examples of PRRs include MBL, pulmonary surfactant protein, C-reactive protein, toll-like receptors (TLRs), C-Type lectin, NOD, and MX. The PRRs recognize PAMPs or pathogen associated molecular patterns which can trigger cytokine release. Examples of PAMPs include LPS (endotoxin), peptidoglycan (cell walls), lipoproteins (bacterial capsules), hypomethylated DNA (CpG found in bacteria and parasites), double-stranded DNA (viruses), and flagellin (bacterial flagella). These antigens are produced by microbal cells and not by human cells. Recognition of PAMPs by PRRs leads to complement activation, opsonization, cytokine release, and phagocyte activation. [1],[4],[5],[6]

Finally, the mononuclear phagocytes and granulocytic cells are also important to the innate response and help link the innate immune response to the adaptive immune response. Mononuclear phagocytes include monocytes which circulate in the blood and macrophages which are in the tissues. Monocytes and macrophages are highly important in antigen presentation, phagocytosis, cytokine production, and antimicrobial and cytotoxic activities. [7]

Upon maturity of the monocytes, the monocytes circulate in the blood for approximately 8 h, then migrate into the tissues and differentiate into specific tissue macrophages or into dendritic cells. There are several types of dendritic cells which are involved in different aspects of immune functions. Many dendritic cells are important in presenting antigen to T-helper cells. However, follicular dendritic cells are found only in lymph follicles and are involved in the binding of antigen-antibody complexes in lymph nodes.[1],[6],[7]

Granulocytic cells include neutrophils, eosinophils, and basophils/mast cells. Neutrophils are highly active phagocytic cells and generally arrive first at a site of inflammation. Eosinophils are also phagocytic cells; however, they are more important in resistance to parasites. Basophils in the blood and mast cells in the tissues release histamine and other substances and are important in the development of allergies. [1],[7]

The innate system may be able to eradicate the pathogenic agent without further assistance from the adaptive system; or, the innate system may stimulate the adaptive immune system to become involved in eradicating the pathogenic agent. [1],[4]

In contrast to the innate immune system, the actions of adaptive immune system are specific to the particular pathogenic agent. This response will take longer to occur than the innate response. However, the adaptive immune system has memory which means that the adaptive immune system will respond more rapidly to that particular pathogen with each successive exposure. [4]

The adaptive immune response is composed of the B-cells/antibodies and T-cells. These are the two arms of the adaptive immune system. The B-cells and antibodies compose humoral immunity or antibody-mediated immunity; and, the T-cells compose cell-mediated immunity. As a note, natural killer cells are also from the lymphocyte lineage like B-cells and T-cells; however, natural killer cells are only involved in innate immune responses. [1],[7]

The first arm of the adaptive immune system is humoral immunity, functions against extracellular pathogenic agents and toxins. B-cells are produced in the bone marrow and then travel to the lymph nodes. Within the lymph nodes, naïve B-cells continue to mature and are exposed to pathogenic agents caught in the particular lymph node. Unlike T-cells, B-cells can recognize antigens in their native form which means that B-cells can recognize antigens without requiring that the antigen be processed by an antigen-presenting cell and then presented by a T-helper cell. [4] These antigens are called T-independent antigens because T-cell activation is not required to activate the B-cells. Examples of these T-independent antigens include lipopolysaccharide, dextran, and bacterial polymeric flagellin. These antigens are typically large polymeric molecules with repeating antigenic determinants. These antigens can also induce numerous B-cells to activate; however, the immune response is weaker and the induction of memory is weaker than with T-helper cell activation. In contrast, activation of B-cells with T-helper cell activation results in a much better immune response and more effective memory. This long-term, effective immune response is the type of reaction that is the goal of immunizations. [1] With the binding of the antigen to the Fab region on the B-cell receptor and secondary signaling from cytokines released by T-helper cells, B-cells begin somatic hypermutation at the Fab region which further increases the corresponding fit between the Fab region and the antigen. This process then stimulates the B-cell(s) to mature into a plasma cell(s) which then begins production of the particular antibody with the best corresponding fit to the antigen. [1]

From these stimulated B-cells, clones of B-cells with the specificity for the particular antigen will arise. These cells may become plasma cells producing antibodies or memory cells which will remain in the lymph nodes to stimulate a new immune response to that particular antigen. This occurs during the primary immune response when the immune system is first exposed to a particular antigen. [4]

This process of clonal selection and expansion will take several days to occur; and, primarily involves the production of IgM. IgM is the first antibody produced during a primary immune response. [7]

As the immune response progresses, the activated plasma cells will begin producing IgG specific to the particular antigen. Although IgM is the first antibody produced and is a much larger antibody, IgG is a better neutralizing antibody. IgG binds more effectively to the antigen and aids in opsonization. [1]

As a note, other antibodies can be produced by plasma cells. These antibodies include IgD, IgA, and IgE. IgD is primarily found as a receptor bound to the surfaces of mature B-cells. While, IgA is the antibody found in secretions such as mucous, saliva, tears, and breast milk; and, IgE is the antibody involved in allergic reactions and parasitic infections. However, the most important antibody for vaccines is IgG. [7]

With the memory cells that have been produced with the primary immune response, any succeeding exposures to the antigen will result in a more rapid and effective secondary immune response. With this secondary immune response, the reaction will be quicker, larger, and primarily composed of IgG. [7]

As for the other arm of adaptive immunity, cell-mediated immunity, it functions primarily against intracellular pathogens. T-cells mature in the thymus and are then released into the bloodstream. There are two main types of T-cells, CD4 cells and CD8 cells. [1],[4]

CD4 cells or T-helper cells have the CD4 co-receptor and only recognize the major histocompatibility complex (MHC) II protein. The MHC II protein is found on all immune cells and acts as a marker of immune cells.

CD4 cells are essential for antibody-mediated immunity and in helping B-cells control extracellular pathogens. There are two subsets of CD4 cells, Th1 and Th2. Th1 cells help promote cell-mediated immunity; and, Th2 cells help promote antibody-mediated immunity. [1],[4]

CD8 cells or T-cytotoxic cells have the CD8 co-receptor and only recognize the major histocompatibility complex (MHC) I protein. The MHC I protein is found on all nucleated body cells except for mature erythrocytes and acts as a marker of body cells. CD8 cells are essential for cell-mediated immunity and in helping control of intracellular pathogens. [1],[4]

Unlike B-cells, T-cells can only recognize antigen that has been processed and presented by antigen-presenting cells. There are two types of antigen processing. [4],[7]

The first type of antigen processing involves attaching intracellular antigens along with MHC I proteins to the surface of antigen-processing cells. This occurs with viral antigens and tumor cells. [1]

The other type of antigen processing involves attaching extracellular antigens along with MHC II proteins to the surface of antigen-presenting cells. This occurs with bacterial and parasitic antigens. [1]

Once the T-cell has been activated by the antigen-presenting cell, it begins to carry out its functions depending on whether it is a CD4 cell or a CD8 cell. As with B-cells, activated T-cells also undergo clonal expansion which produces additional effector T-cells for the current infection and memory T-cells for future infections with this antigen. [1]

   Types of Immunization Top

Immunization can be derived from either passive or active means. These means can be from either natural or artificial sources. Natural sources are due to exposure to the environment, humans, and animals. In contrast, artificial sources are due to medical interventions.

Passive immunization occurs with the transfer to preformed antibodies to an unimmunized individual. This individual would then develop a temporary immunity to a particular organism or toxin due to the presence of these preformed antibodies. Once these preformed antibodies have been destroyed, the individual would no longer have immunity to this microorganism or toxin. [8]

Passive immunization can occur either naturally or artificially. Excellent examples of natural passive immunization are the passage of maternal antibodies through the placenta to the fetus and the passage of these maternal antibodies to the infant through the colostrum and milk. [1],[9]

Excellent examples of artificial passive immunization include the administration of pooled human immune gamma globulin and antivenin. These gamma globulins and antivenins provide temporary immunity to either a particular illness or venom. Concurrent with these effects of this temporary immunity from the preformed antibodies, the individual's own body is likely to be in the early stages of developing its own active immune response. [1]

Active immunization occurs with the exposure of an unimmunized individual to a pathogenic agent. The immune system of this individual then begins the process of developing immunity to this agent. In contrast to passive immunization, active immunization typically produces long-term immunity due to the stimulation of the individual's immune system. The process of stimulating the immune system against a pathogenic agent will be further discussed in this article. [9]

Active immunization can occur either naturally or artificially. An excellent example of natural active immunization is exposure to influenza. The body then begins the process of developing long-term immunity to the influenza virus.

Excellent examples of artificial active immunization include the different types of immunizations that will be discussed in this article. These immunizations mimic the stimulation necessary for immune development yet do not produce active disease. [1],[9]

   Stimulation of Immunity by Vaccines Top

As with any challenge to the immune system, the body must first detect the threat whether it is a pathogenic agent or an immunization. This initial detection typically is done by the innate immune system; although, B-cells may also perform this function. This detection process begins when the immune system recognizes epitopes on antigens. Epitopes are small subregions on the antigens that simulate immune recognition.

Multiple components of the innate immune system will then respond to this challenge. These components of innate immunity will opsonize or bind to the agent and aid in its engulfment by antigen-presenting cells such as macrophages or monocytes. These antigen-presenting cell(s) will then process the antigens from this pathogenic agent and insert the processed antigen along with the MHC protein onto the surface on the antigen-presenting cell. [10]

If it is a viral antigen, the antigen will be bound with MHC I protein and presented by the antigen-presenting cell to a CD8 cell which will likely trigger cell-mediated immunity. If it is a bacterial or parasitic antigen, the antigen will be bound with MHC II protein and presented by the antigen-presenting cell to a CD4 cell which will likely trigger antibody-mediated immunity. [1]

   Current/Under Development Vaccine Types Top

There are a variety of vaccine types that are either currently in use or in development for the prevention of infectious diseases. Under ideal conditions, vaccines should trigger the innate immune system and both arms of the adaptive immune system. [11] However, each vaccine type has both advantages and disadvantages which can affect the stimulation of the immune system and thus limit the usefulness of the vaccine type. [12]

First, live, attenuated vaccines as exemplified by the vaccines against measles, mumps, and chickenpox contain laboratory-weakened versions of the original pathogenic agent. Therefore, these vaccines produce a strong cellular and antibody responses and typically produce long-term immunity with only one to two doses of vaccine. Typically, it is less difficult to create live, attenuated vaccines with viruses rather than bacteria because viruses have fewer genes so it is easier to control the viral characteristics. However, because these vaccines contain living microorganisms, refrigeration is required to preserve potency; and, there is the possibility of reversion to the original virulent form of the pathogenic agent. In addition, live vaccines cannot be given to individuals with weakened immune systems because the vaccine produces actual disease.

Inactivated vaccines as exemplified by the inactivated influenza vaccine are produced by destroying a pathogenic agent with chemicals, heat, or radiation. This inactivation of the microorganism makes the vaccine more stable. These vaccines do not require refrigeration and can be freeze-dried for transport. However, these vaccines produce weaker immune responses therefore additional booster shots are required to maintain immunity. [12]

In experiments with mice by Raz et al., a vaccine made from irradiated Listeria monocytogenes bacteria, rather than heat-killed bacteria, showed protection against a challenge with live Listeria. The irradiated vaccine also stimulated a protective response from T-cells which previously had only been shown to occur with vaccines made from live, weakened Listeria bacteria. [11]

Subunit vaccines as exemplified by the recombinant hepatitis B vaccine include only epitopes (specific parts of antigens to which antibodies or T-cells recognize and bind) that most readily stimulate the immune system. Because these vaccines only use a few specific antigens, this reduces the likelihood of adverse reactions; however, this specificity increases the difficulty of determining which antigens should be included in the vaccine.

Toxoid vaccines as exemplified by the diphtheria and tetanus vaccines are produced by inactivating bacterial toxins with formalin. These toxoids stimulate an immune response against the bacterial toxins.

Conjugate vaccines as exemplified by the Haemophilus influenzae type B (Hib) vaccine are a special type of subunit vaccine. In a conjugate vaccine, antigens or toxoids from a microbe are linked to polysaccharides from the outer coating of that microbe to stimulate immunity (especially in infants).

Naked DNA vaccines are still in the experimental stages of development. These vaccines would use DNA specific for microbial antigens to stimulate immunity. This DNA would be administered by injection and then body cells would take up the DNA.

These body cells would then start producing the antigen and displaying it on their surfaces which would then stimulate the immune system. These vaccines would produce both a strong antibody response to the free antigen and a strong cellular response to the microbial antigens displayed on the cell surfaces. These vaccines are also considered relatively easy and inexpensive to create and produce. Naked DNA vaccines for influenza and herpes are still in the developmental stages. [12]

Recombinant vector vaccines are experimental vaccines that use either an attenuated virus or microbe to introduce microbial DNA into body cells. These viral vaccines would readily mimic a natural infection thus stimulating the immune system.

Attenuated bacteria could also have genetic material for antigens from a pathogenic microbe inserted. These antigens from the pathogenic microbe would then be displayed on the harmless microbe this mimicking the pathogen and stimulating the immune system. Both bacterial and viral-based recombinant vectors vaccines for HIV, rabies, and measles are in the experimental stages. [12]

In addition to these vaccines, there have been studies examining the possibility of improving vaccine adjuvants which would target the innate immune system. These adjuvants would fall into two classes, either delivery systems (such as cationic microparticles) or immune potentiators (such as cytokines or PRRs). The delivery systems would possibly be used to concentrate and display antigens in repetitious patterns, to assist in localizing antigens and immune potentiators, and to target the antigens in the vaccine to the antigen-presenting cells. While, the immune potentiators would be used activate the innate immune system directly. [6]

   Summary Top

Both the innate and adaptive immune subsystems are necessary to provide an effective immune response whether to an actual pathogenic agent or to an immunization. Further, effective immunizations must induce long-term stimulation of both the humoral and cell-mediated arms of the adaptive system by the production of effector cells for the current infection and memory cells for future infections with the pathogenic agent. At least seven different types of vaccines are currently in use or in development that produce this effective immunity and have contributed greatly to the prevention of infectious disease around the world.

   References Top

1.Goldsby RA, Kindt TJ, Osborne BA, Kuby J. Immunology. 5th ed. New York: Freeman; 2003.  Back to cited text no. 1
2.Hartshorn KL, White MR, Crouch EC. Contributions of the N- and C-terminal domains of surfactant protein D to the binding, aggregation, and phagocytic uptake of bacteria. Infect Immun 2002;70:6129-39.  Back to cited text no. 2
3.The Merck Manuals Online Medical Library. 2008. Complement System. Available from: [Last cited on 2009 Nov 22].  Back to cited text no. 3
4.Margolick JB, Markham RB, Scott AL. The immune system and host defense against infections. In: Nelson KE, Masters CF, editors. Infectious Disease Epidemiology: Theory and Practice. Chapter 10. 2nd ed. Boston: Jones and Bartlett; 2006. p. 317-43.  Back to cited text no. 4
5.Janssens S, Beyaert R. Role of toll-like receptors in pathogen recognition. Clin Microbiol Rev 2003;16:637-46.  Back to cited text no. 5
6.Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 2005;11:S63-8.  Back to cited text no. 6
7.The Merck Manuals Online Medical Library. 2008. Components of the Immune System. Available from: [Last cited on 2009 Nov 26].  Back to cited text no. 7
8.The Merck Manuals Online Medical Library.2008. Passive Immunization. Available from: [Last cited on 2009 Dec 5].  Back to cited text no. 8
9.Centers for Disease Control and Prevention. 2009. Immunity Types. Available from: [Last cited on 2009 Dec 20].  Back to cited text no. 9
10.Schijns VE. (2001). Activation and programming of adaptive immune responses by vaccine adjuvants. Available from: [Last cited on 2010 Jan 7].  Back to cited text no. 10
11.NIH News. 2006. Radiation-killed bacteria vaccine induces broad immune response in mice. Available from: [Last cited on 2010 Jan 7].  Back to cited text no. 11
12.National Institute of Allergy and Infectious Diseases. 2009. Types of Vaccines. Available from: [Last cited on 2009 Dec 22].  Back to cited text no. 12

Correspondence Address:
Angela S Clem
Department of Global Health, College of Public Health, University of South Florida, Tampa, FL
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0974-777X.77299

Rights and Permissions

This article has been cited by
1 The search for a Buruli Ulcer vaccine and the effectiveness of the Bacillus Calmette–Guérin vaccine
Tamara Z. Ishwarlall, Moses Okpeku, Adebayo A Adeniyi, Matthew A. Adeleke
Acta Tropica. 2022; : 106323
[Pubmed] | [DOI]
2 Toward rational vaccine engineering
Yashavantha L. Vishweshwaraiah, Nikolay V. Dokholyan
Advanced Drug Delivery Reviews. 2022; 183: 114142
[Pubmed] | [DOI]
3 Dendritic cell activation by a micro particulate based system containing the influenza matrix-2 protein virus-like particle (M2e VLP)
Kimberly Braz Gomes, Grace Lovia Allotey-Babington, Sucheta D'Sa, Sang-Moo Kang, Martin J. D'Souza
International Journal of Pharmaceutics. 2022; : 121667
[Pubmed] | [DOI]
4 Mechanisms underpinning poor antibody responses to vaccines in ageing
Jia Le Lee, Michelle A Linterman
Immunology Letters. 2022; 241: 1
[Pubmed] | [DOI]
5 Mucosal immune responses to infection and vaccination in the respiratory tract
Robert C. Mettelman, E. Kaitlynn Allen, Paul G. Thomas
Immunity. 2022; 55(5): 749
[Pubmed] | [DOI]
6 Quantitative and qualitative features of acute phase-adverse events following SARS-CoV-2 vaccination in a large sample of people with multiple sclerosis
E. Tavazzi, G. Della Porta, F.S. Robustelli della Cuna, L. Gervasio, E. Guerra, M.A. Tejada Condemayta, A. Filosa, C. Montomoli, R. Bergamaschi
Multiple Sclerosis and Related Disorders. 2022; 68: 104120
[Pubmed] | [DOI]
7 Characterization of Prostanoids Response to Bordetella pertussis Antigen BscF and Tdap in LPS-challenged monocytes
Md. Obayed Raihan, Brenna M. Espelien, Courtney Hanson, Brett A. McGregor, Nathan A. Velaris, Travis D. Alvine, Svetlana Al Golovko, David S. Bradley, Matthew Nilles, Mikhail Y. Glovko, Junguk Hur, James E. Porter
Prostaglandins, Leukotrienes and Essential Fatty Acids. 2022; : 102452
[Pubmed] | [DOI]
8 Enhancement of live vaccines by co-delivery of immune modulating proteins
Megha M. Manohar, Bronwyn E. Campbell, Anna K. Walduck, Robert J. Moore
Vaccine. 2022;
[Pubmed] | [DOI]
9 COVID-19 Vaccines: Update of the vaccines in use and under development
Rafaela Angotti Marta, Gisele Emy Kondo Nakamura, Bruno de Matos Aquino, Paulo R. Bignardi
Vacunas. 2022;
[Pubmed] | [DOI]
10 Variant-specific vaccination induces systems immune responses and potent in vivo protection against SARS-CoV-2
Lei Peng, Paul A. Renauer, Arya Ökten, Zhenhao Fang, Jonathan J. Park, Xiaoyu Zhou, Qianqian Lin, Matthew B. Dong, Renata Filler, Qiancheng Xiong, Paul Clark, Chenxiang Lin, Craig B. Wilen, Sidi Chen
Cell Reports Medicine. 2022; 3(5): 100634
[Pubmed] | [DOI]
11 T helper type (Th1/Th2) responses to SARS-CoV-2 and influenza A (H1N1) virus: From cytokines produced to immune responses
Elahe Aleebrahim-Dehkordi, Bahareh Molavi, Melika Mokhtari, Niloofar Deravi, Mobina Fathi, Tara Fazel, Mehdi Mohebalizadeh, Pooneh Koochaki, Parnian Shobeiri, Ali Hasanpour-Dehkordi
Transplant Immunology. 2022; 70: 101495
[Pubmed] | [DOI]
12 Designing ferritin nanocage based vaccine candidates for SARS-CoV-2 by in silico engineering of its HLA I and HLA II epitope peptides
Pratibha Manickavasagam, Suman Abhishek, Eerappa Rajakumara
Journal of Biomolecular Structure and Dynamics. 2022; : 1
[Pubmed] | [DOI]
13 Is Hepatitis-B Immunization Effective During Chronic Liver Fibrosis? Investigation of Secretory and Cellular Immune Responses on an Experimental Model
Basak Kayhan, Zeynal Mete Karaca, Esra Canpolat, Veysel Ersan, Mehmet Gül, Saim Yologolu, Sezai Yilmaz
Immunopharmacology and Immunotoxicology. 2022; : 1
[Pubmed] | [DOI]
14 Dendritic cell-based vaccine: the state-of-the-art vaccine platform for COVID-19 management
Vivek P. Chavda, Aayushi B. Patel, Lalitkumar K. Vora, Vasso Apostolopoulos, Bruce D. Uhal
Expert Review of Vaccines. 2022; : 1
[Pubmed] | [DOI]
15 The anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, minimally impacts the endogenous immune response to COVID-19 vaccination
Robert J. Benschop, Jay L. Tuttle, Lin Zhang, Josh Poorbaugh, Nicole L. Kallewaard, Peter Vaillancourt, Melissa Crisp, Thi Ngoc Vy Trinh, Joshua J. Freitas, Stephanie Beasley, Montanea Daniels, Natalie Haustrup, Richard E. Higgs, Ajay Nirula, Myron S. Cohen, Mary Marovich
Science Translational Medicine. 2022;
[Pubmed] | [DOI]
16 Methotrexate Treatment Suppresses Monocytes in Nonresponders to Pneumococcal Conjugate Vaccine in Rheumatoid Arthritis Patients
Evelina Elmér, Per Nived, Åsa Pettersson, Lillemor Skattum, Thomas Hellmark, Meliha C. Kapetanovic, Åsa C. M. Johansson, Dawei Cui
Journal of Immunology Research. 2022; 2022: 1
[Pubmed] | [DOI]
17 Application of microneedle patches for drug delivery; doorstep to novel therapies
Fateme Nazary Abrbekoh, Leila Salimi, Sepideh Saghati, Hassan Amini, Sonia Fathi Karkan, Keyvan Moharamzadeh, Emel Sokullu, Reza Rahbarghazi
Journal of Tissue Engineering. 2022; 13: 2041731422
[Pubmed] | [DOI]
18 Response to SARS-CoV-2 vaccines in patients receiving B-cell modulating antibodies for renal autoimmune disease
Frederic Arnold, Daniela Huzly, Yakup Tanriver, Thomas Welte
BMC Infectious Diseases. 2022; 22(1)
[Pubmed] | [DOI]
19 COVID-19 vaccination in Nigeria: A rapid review of vaccine acceptance rate and the associated factors
Oluwatosin Olu-Abiodun, Olumide Abiodun, Ngozi Okafor, Nusirat Elelu
PLOS ONE. 2022; 17(5): e0267691
[Pubmed] | [DOI]
20 Differences in B-Cell Immunophenotypes and Neutralizing Antibodies Against SARS-CoV-2 After Administration of BNT162b2 (Pfizer-BioNTech) Vaccine in Individuals with and without Prior COVID-19 - A Prospective Cohort Study
José Javier Morales-Núñez, Mariel García-Chagollán, José Francisco Muñoz-Valle, Saúl Alberto Díaz-Pérez, Paola Carolina Torres-Hernández, Saraí Citlalic Rodríguez-Reyes, Guillermo Santoscoy-Ascencio, José Julio Sierra García de Quevedo, Jorge Hernández-Bello
Journal of Inflammation Research. 2022; Volume 15: 4449
[Pubmed] | [DOI]
21 Local and Systemic Immunity Are Impaired in End-Stage-Renal-Disease Patients Treated With Hemodialysis, Peritoneal Dialysis and Kidney Transplant Recipients Immunized With BNT162b2 Pfizer-BioNTech SARS-CoV-2 Vaccine
Magdalena Piotrowska, Maciej Zielinski, Leszek Tylicki, Bogdan Biedunkiewicz, Alicja Kubanek, Zuzanna Slizien, Karolina Polewska, Piotr Tylicki, Marta Muchlado, Justyna Sakowska, Marcin Renke, Adam Sudol, Malgorzata Dabrowska, Monika Lichodziejewska-Niemierko, Tomasz Smiatacz, Alicja Debska-Slizien, Piotr Trzonkowski
Frontiers in Immunology. 2022; 13
[Pubmed] | [DOI]
22 Editorial: Research, Development and Clinical Trials for Peptide-Based Vaccines
Shisong Jiang, Min Gong, Xiao-Ning Xu
Frontiers in Immunology. 2022; 13
[Pubmed] | [DOI]
23 Acute Vertigo After COVID-19 Vaccination: Case Series and Literature Review
Paola Di Mauro, Ignazio La Mantia, Salvatore Cocuzza, Pasqua Irene Sciancalepore, Deborak Rasà, Antonino Maniaci, Salvatore Ferlito, Isabella Tundo, Roberta Anzivino
Frontiers in Medicine. 2022; 8
[Pubmed] | [DOI]
24 Acute Unilateral Peripheral Vestibulopathy After COVID-19 Vaccination: Initial Experience in a Tertiary Neurotology Center
Marc Basil Schmid, David Bächinger, Athina Pangalu, Dominik Straumann, Julia Dlugaiczyk
Frontiers in Neurology. 2022; 13
[Pubmed] | [DOI]
25 Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC
Rachel Evans, Kelvin Lee, Paul K. Wallace, Mary Reid, Jason Muhitch, Askia Dozier, Circe Mesa, Patricia L. Luaces, Orestes Santos-Morales, Adrienne Groman, Carlos Cedeno, Aileen Cinquino, Daniel T. Fisher, Igor Puzanov, Mateusz Opyrchal, Christos Fountzilas, Tong Dai, Marc Ernstoff, Kristopher Attwood, Alan Hutson, Candace Johnson, Zaima Mazorra, Danay Saavedra, Kalet Leon, Agustin Lage, Tania Crombet, Grace K. Dy
Frontiers in Oncology. 2022; 12
[Pubmed] | [DOI]
26 Audiovestibular Disorders after COVID-19 Vaccine: Is There an Association?
Davide Pisani, Federico Maria Gioacchini, Pasquale Viola, Alfonso Scarpa, Alessia Astorina, Massimo Re, Gianmarco Marcianò, Francesco Manti, Roberta Anzivino, Giuseppe Chiarella
Audiology Research. 2022; 12(3): 212
[Pubmed] | [DOI]
27 Comparative Reverse Vaccinology of Piscirickettsia salmonis, Aeromonas salmonicida, Yersinia ruckeri, Vibrio anguillarum and Moritella viscosa, Frequent Pathogens of Atlantic Salmon and Lumpfish Aquaculture
Joy Chukwu-Osazuwa, Trung Cao, Ignacio Vasquez, Hajarooba Gnanagobal, Ahmed Hossain, Vimbai Irene Machimbirike, Javier Santander
Vaccines. 2022; 10(3): 473
[Pubmed] | [DOI]
28 Immunoinformatics and Biophysics Approaches to Design a Novel Multi-Epitopes Vaccine Design against Staphylococcus auricularis
Roba Attar, Eid A. Alatawi, Faris F. Aba Alkhayl, Khloud Nawaf Alharbi, Khaled S. Allemailem, Ahmad Almatroudi
Vaccines. 2022; 10(5): 637
[Pubmed] | [DOI]
29 An In-Silico Investigation to Design a Multi-Epitopes Vaccine against Multi-Drug Resistant Hafnia alvei
Fahad M. Alshabrmi, Faris Alrumaihi, Sahar Falah Alrasheedi, Wafa Abdullah I. Al-Megrin, Ahmad Almatroudi, Khaled S. Allemailem
Vaccines. 2022; 10(7): 1127
[Pubmed] | [DOI]
30 Microneedle Delivery of an Adjuvanted Microparticulate Vaccine Induces High Antibody Levels in Mice Vaccinated against Coronavirus
Sharon Vijayanand, Smital Patil, Devyani Joshi, Ipshita Menon, Keegan Braz Gomes, Akanksha Kale, Priyal Bagwe, Shadi Yacoub, Mohammad N. Uddin, Martin J. D’Souza
Vaccines. 2022; 10(9): 1491
[Pubmed] | [DOI]
31 Possible Correlations between the COVID-19 mRNA Vaccine and Contracting Myocarditis/Pericarditis in Young Adults
Carl Dowling
Journal of Biomedical Research & Environmental Sciences. 2022; 3(4): 453
[Pubmed] | [DOI]
32 Can the SARS-CoV-2 Omicron Variant Confer Natural Immunity against COVID-19?
Abdul Hawil Abas, Siti Marfuah, Rinaldi Idroes, Diah Kusumawaty, Fatimawali, Moon Nyeo Park, Abolghasem Siyadatpanah, Fahad A. Alhumaydhi, Shafi Mahmud, Trina Ekawati Tallei, Talha Bin Emran, Bonglee Kim
Molecules. 2022; 27(7): 2221
[Pubmed] | [DOI]
33 Introducing B Cell Epitopes of Newcastle Disease Virus Obtained from Domestic Pigeons (Columba livia domestica) as Sub-Unit Vaccine Candidate to Eradicate Newcastle Disease Virus in Poultry
Jola Rahmahani, Tetri Regilya Fatimah, Anastasia Hanny Irawan, Naimah Putri, Eryk Hendrianto, Fedik Abdul Rantam
Research Journal of Pharmacy and Technology. 2022; : 2059
[Pubmed] | [DOI]
34 Vaccinations in patients with multiple sclerosis: review and recommendations
Cassie Nesbitt, Louise Rath, Michael Zhong, Allen C Cheng, Helmut Butzkueven, Robb Wesselingh, Olga Skibina, Mastura Monif, Wei Yeh, Julia ML Brotherton, Stephen Reddel, Anneke Van Der Walt
Medical Journal of Australia. 2021; 214(8): 350
[Pubmed] | [DOI]
35 COVID-19 Vaccine: Critical Questions with Complicated Answers
Mohammad Faisal Haidere, Zubair Ahmed Ratan, Senjuti Nowroz, Sojib Bin Zaman, You-Jung Jung, Hassan Hosseinzadeh, Jae Youl Cho
Biomolecules & Therapeutics. 2021; 29(1): 1
[Pubmed] | [DOI]
36 Vaccine in response to COVID-19: Recent developments, challenges, and a way out
Sameer Quazi
Biomedical and Biotechnology Research Journal (BBRJ). 2021; 5(2): 105
[Pubmed] | [DOI]
37 COVID-19 vaccines: A ray of hope
Neha Chand, Rajani Mathur, Shridhar Dwivedi
Indian Journal of Medical Specialities. 2021; 12(4): 188
[Pubmed] | [DOI]
38 A comprehensive insight on the COVID-19 vaccine candidates
Anu Sharma, RaviPrakash Sharma, Rimplejeet Kaur, Ria Sharma, Surjit Singh
Journal of Family Medicine and Primary Care. 2021; 10(7): 2457
[Pubmed] | [DOI]
39 Development of Fish Parasite Vaccines in the OMICs Era: Progress and Opportunities
Saloni Shivam, Mansour El-Matbouli, Gokhlesh Kumar
Vaccines. 2021; 9(2): 179
[Pubmed] | [DOI]
40 Chemical Conjugation Strategies for the Development of Protein-Based Subunit Nanovaccines
Lantian Lu, Viet Tram Duong, Ahmed O. Shalash, Mariusz Skwarczynski, Istvan Toth
Vaccines. 2021; 9(6): 563
[Pubmed] | [DOI]
41 Analysis of Host Immunological Response of Adenovirus-Based COVID-19 Vaccines
Suzan Farhang-Sardroodi, Chapin S. Korosec, Samaneh Gholami, Morgan Craig, Iain R. Moyles, Mohammad Sajjad Ghaemi, Hsu Kiang Ooi, Jane M. Heffernan
Vaccines. 2021; 9(8): 861
[Pubmed] | [DOI]
42 Recombinant Antigen of Type 2 Porcine Reproductive and Respiratory Syndrome Virus (PRRSV-2) Promotes M1 Repolarization of Porcine Alveolar Macrophages and Th1 Type Response
Rika Wahyuningtyas, Yin-Siew Lai, Mei-Li Wu, Hsin-Wei Chen, Wen-Bin Chung, Hso-Chi Chaung, Ko-Tung Chang
Vaccines. 2021; 9(9): 1009
[Pubmed] | [DOI]
43 COVID-19 Vaccine Platforms: Challenges and Safety Contemplations
Hadeel T. Al-Jighefee, Hoda Najjar, Muna Nizar Ahmed, Abeer Qush, Sara Awwad, Layla Kamareddine
Vaccines. 2021; 9(10): 1196
[Pubmed] | [DOI]
44 A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues
Shahad Saif Khandker, Brian Godman, Md. Irfan Jawad, Bushra Ayat Meghla, Taslima Akter Tisha, Mohib Ullah Khondoker, Md. Ahsanul Haq, Jaykaran Charan, Ali Azam Talukder, Nafisa Azmuda, Shahana Sharmin, Mohd. Raeed Jamiruddin, Mainul Haque, Nihad Adnan
Vaccines. 2021; 9(12): 1387
[Pubmed] | [DOI]
45 A Review of UK-Registered and Candidate Vaccines for Bovine Respiratory Disease
Joanne L. Lemon, Michael J. McMenamy
Vaccines. 2021; 9(12): 1403
[Pubmed] | [DOI]
46 Update on the Inactivation Procedures for the Vaccine Development Prospects of a New Highly Virulent RGNNV Isolate
Alberto Falco, Melissa Bello-Perez, Rocío Díaz-Puertas, Matthew Mold, Mikolaj Adamek
Vaccines. 2021; 9(12): 1441
[Pubmed] | [DOI]
47 Factor Influences for Diagnosis and Vaccination of Avian Infectious Bronchitis Virus (Gammacoronavirus) in Chickens
Md. Safiul Alam Bhuiyan, Zarina Amin, Ag Muhammad Sagaf Abu Bakar, Suryani Saallah, Noor Hydayaty Md. Yusuf, Sharifudin Md. Shaarani, Shafiquzzaman Siddiquee
Veterinary Sciences. 2021; 8(3): 47
[Pubmed] | [DOI]
48 Immune responses induced by different vaccine platforms against coronavirus disease-19
Eknath D. Ahire, Sanjay J Kshirsagar
Exploration of Immunology. 2021; : 243
[Pubmed] | [DOI]
49 COVID-19 Vaccines: Current Conditions and Future Prospects
Tarek Zieneldien, Janice Kim, Jessica Cao, Chuanhai Cao
Biology. 2021; 10(10): 960
[Pubmed] | [DOI]
50 Remission-Stage Ovarian Cancer Cell Vaccine with Cowpea Mosaic Virus Adjuvant Prevents Tumor Growth
Courtney T. Stump, Gregory Ho, Chenkai Mao, Frank A. Veliz, Veronique Beiss, Jennifer Fields, Nicole F. Steinmetz, Steven Fiering
Cancers. 2021; 13(4): 627
[Pubmed] | [DOI]
51 Recent Development of Ruminant Vaccine Against Viral Diseases
Sk Mohiuddin Choudhury, XuSheng Ma, Wen Dang, YuanYuan Li, HaiXue Zheng
Frontiers in Veterinary Science. 2021; 8
[Pubmed] | [DOI]
52 Tailored Nanoparticles as Vaccine Components
Alina Popa, Sebastian Springer
Applied Sciences. 2021; 11(24): 11898
[Pubmed] | [DOI]
53 What Could Explain the Lower COVID-19 Burden in Africa despite Considerable Circulation of the SARS-CoV-2 Virus?
Richard G. Wamai, Jason L. Hirsch, Wim Van Damme, David Alnwick, Robert C. Bailey, Stephen Hodgins, Uzma Alam, Mamka Anyona
International Journal of Environmental Research and Public Health. 2021; 18(16): 8638
[Pubmed] | [DOI]
54 Current Immunological and Clinical Perspective on Vaccinations in Multiple Sclerosis Patients: Are They Safe after All?
Shani Witman Tsur, Eli Adrian Zaher, Meydan Tsur, Karolina Kania, Alicja Kalinowska-Lyszczarz
International Journal of Molecular Sciences. 2021; 22(8): 3859
[Pubmed] | [DOI]
55 COVID-19: Insights into Potential Vaccines
Ke-Yan Loo, Vengadesh Letchumanan, Hooi-Leng Ser, Siew Li Teoh, Jodi Woan-Fei Law, Loh Teng-Hern Tan, Nurul-Syakima Ab Mutalib, Kok-Gan Chan, Learn-Han Lee
Microorganisms. 2021; 9(3): 605
[Pubmed] | [DOI]
56 Beyond Just Peptide Antigens: The Complex World of Peptide-Based Cancer Vaccines
Alexander J. Stephens, Nicola A. Burgess-Brown, Shisong Jiang
Frontiers in Immunology. 2021; 12
[Pubmed] | [DOI]
57 Hijacking of the Host’s Immune Surveillance Radars by Burkholderia pseudomallei
Vanitha Mariappan, Kumutha Malar Vellasamy, Muttiah Barathan, A. S. Smiline Girija, Esaki M. Shankar, Jamuna Vadivelu
Frontiers in Immunology. 2021; 12
[Pubmed] | [DOI]
58 Molecular and Clinical Aspects of COVID-19 Vaccines and Other Therapeutic Interventions Apropos Emerging Variants of Concern
Khursheed Ul Islam, Thoraya Mohamed Elhassan A-Elgadir, Sarah Afaq, Tanveer Ahmad, Jawed Iqbal
Frontiers in Pharmacology. 2021; 12
[Pubmed] | [DOI]
59 The Development of mRNA Vaccines for Infectious Diseases: Recent Updates
Nitika, Jiao Wei, Ai-Min Hui
Infection and Drug Resistance. 2021; Volume 14: 5271
[Pubmed] | [DOI]
60 Knowledge and Attitudes of Young Adults Towards Donation of COVID-19 Convalescent Plasma and Its Therapeutic Properties
Lidia Perenc, Ryszard Peczkowski
Journal of Blood Medicine. 2021; Volume 12: 709
[Pubmed] | [DOI]
61 The PentaFOLD 3.0 Algorithm for the Selection of Stable Elements of Secondary Structure to be Included in Vaccine Peptides
Vladislav V. Khrustalev
Protein & Peptide Letters. 2021; 28(5): 573
[Pubmed] | [DOI]
62 An Updated Overview of Herpes Simplex Virus-1 Infection: Insights from Origin to Mitigation Measures
Abu Tayab Moin, Mohammad Al-baruni Chowdhury, Sumaiya Hafiz Riana, Md. Asad Ullah, Yusha Araf, Bishajit Sarkar, Abdullah Mohammad Shohael
Electronic Journal of General Medicine. 2021; 18(4): em299
[Pubmed] | [DOI]
Ankara Universitesi Eczacilik Fakultesi Dergisi. 2021; : 109
[Pubmed] | [DOI]
64 Influence of chronic hepatitis C infection on the monocyte-to-platelet ratio: data analysis from the National Health and Nutrition Examination Survey (2009–2016)
Aidan M. Nikiforuk, Mohammad Ehsanul Karim, David M. Patrick, Agatha N. Jassem
BMC Public Health. 2021; 21(1)
[Pubmed] | [DOI]
65 Comprehensive literature review on COVID-19 vaccines and role of SARS-CoV-2 variants in the pandemic
Charles Yap, Abulhassan Ali, Amogh Prabhakar, Akul Prabhakar, Aman Pal, Ying Yi Lim, Pramath Kakodkar
Therapeutic Advances in Vaccines and Immunotherapy. 2021; 9: 2515135521
[Pubmed] | [DOI]
66 Racing to immunity: Journey to a COVID-19 vaccine and lessons for the future
Ester Calvo Fernández, Lucie Y. Zhu
British Journal of Clinical Pharmacology. 2021; 87(9): 3408
[Pubmed] | [DOI]
67 A guide to investigating immune responses elicited by whole-sporozoite pre-erythrocytic vaccines against malaria
Diana Moita, Helena Nunes-Cabaço, António M. Mendes, Miguel Prudêncio
The FEBS Journal. 2021;
[Pubmed] | [DOI]
68 Zebrafish Embryos Immune System induction with BSA as an initial Screening model for Covid-19 Treatment
Dita Arya Widatama, Bambang Retnoaji
IOP Conference Series: Earth and Environmental Science. 2021; 755(1): 012012
[Pubmed] | [DOI]
69 Oral Polio Vaccine to Protect Against COVID-19: Out of the Box Strategies?
Melanie Malave Sanchez, Paul Saleeb, Shyam Kottilil, Poonam Mathur
Open Forum Infectious Diseases. 2021; 8(8)
[Pubmed] | [DOI]
70 Otologic Manifestations After COVID-19 Vaccination: The House Ear Clinic Experience
Helena Wichova, Mia E. Miller, M. Jennifer Derebery
Otology & Neurotology. 2021; 42(9): e1213
[Pubmed] | [DOI]
71 Non-specific effects of veterinary vaccines: a systematic review
Sintayehu M. Arega, Darryn L. Knobel, Felix N. Toka, Anne Conan
Vaccine. 2021;
[Pubmed] | [DOI]
72 Designing a multi-epitope vaccine against Mycobacteroides abscessus by pangenome-reverse vaccinology
Hamza Arshad Dar, Saba Ismail, Yasir Waheed, Sajjad Ahmad, Zubia Jamil, Hafsa Aziz, Helal F. Hetta, Khalid Muhammad
Scientific Reports. 2021; 11(1)
[Pubmed] | [DOI]
73 A comprehensive overview of vaccines developed for pandemic viral pathogens over the past two decades including those in clinical trials for the current novel SARS-CoV-2
Kannan Damodharan, Gandarvakottai Senthilkumar Arumugam, Suresh Ganesan, Mukesh Doble, Sathiah Thennarasu
RSC Advances. 2021; 11(33): 20006
[Pubmed] | [DOI]
74 Vaccination Update for Nurse Practitioners Caring for Adults
Patrick C. Crane
Advances in Family Practice Nursing. 2021; 3: 15
[Pubmed] | [DOI]
75 Positive affect and peripheral inflammatory markers among adults: A narrative review
Dusti R. Jones, Jennifer E. Graham-Engeland
Psychoneuroendocrinology. 2021; 123: 104892
[Pubmed] | [DOI]
76 Early-life exposure to widespread environmental toxicants and children's health risks: A focus on the post-vaccination antibody potency or immunoglobulin levels
Zhijun Zeng, Sieglind Ngai, Qihua Wang, Wanting Liang, Xia Huo
Science of The Total Environment. 2021; 781: 146714
[Pubmed] | [DOI]
77 Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity
Hylemariam Mihiretie Mengist, Arnaud John Kombe Kombe, Daniel Mekonnen, Abtie Abebaw, Melese Getachew, Tengchuan Jin
Seminars in Immunology. 2021; : 101533
[Pubmed] | [DOI]
78 Brain Tumor Vaccines
Justin Lee, Benjamin R. Uy, Linda M. Liau
Neurosurgery Clinics of North America. 2021; 32(2): 225
[Pubmed] | [DOI]
79 B cell therapy and the use of RNA-based COVID-19 vaccines
Anastasia Vishnevetsky, Chris Hawkes, Jeannette Lechner-Scott, Gavin Giovannoni, Michael Levy, Daniela Pohl
Multiple Sclerosis and Related Disorders. 2021; 49: 102887
[Pubmed] | [DOI]
80 In silico CD4+ T-cell multiepitope prediction and HLA distribution analysis for Marburg Virus—A strategy for vaccine designing
Anupam Dhasmana, Swati Dhasmana, Ahmad Alsulimani, Sudhir Kotnala, Vivek Kumar Kashyap, Shafiul Haque, Meena Jaggi, Murali M. Yallapu, Subhash C. Chauhan
Journal of King Saud University - Science. 2021; : 101751
[Pubmed] | [DOI]
81 Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients
Hannah Kelly, Brent Sokola, Hesham Abboud
Journal of Neuroimmunology. 2021; 356: 577599
[Pubmed] | [DOI]
82 Various theranostics and immunization strategies based on nanotechnology against Covid-19 pandemic: An interdisciplinary view
Sujan Chatterjee, Snehasis Mishra, Kaustav Dutta Chowdhury, Chandan Kumar Ghosh, Krishna Das Saha
Life Sciences. 2021; 278: 119580
[Pubmed] | [DOI]
83 Nanocarrier vaccines for SARS-CoV-2
Jatin Machhi, Farah Shahjin, Srijanee Das, Milankumar Patel, Mai Mohamed Abdelmoaty, Jacob D. Cohen, Preet Amol Singh, Ashish Baldi, Neha Bajwa, Raj Kumar, Lalit K. Vora, Tapan A. Patel, Maxim D. Oleynikov, Dhruvkumar Soni, Pravin Yeapuri, Insiya Mukadam, Rajashree Chakraborty, Caroline G. Saksena, Jonathan Herskovitz, Mahmudul Hasan, David Oupicky, Suvarthi Das, Ryan F. Donnelly, Kenneth S. Hettie, Linda Chang, Howard E. Gendelman, Bhavesh D. Kevadiya
Advanced Drug Delivery Reviews. 2021; 171: 215
[Pubmed] | [DOI]
84 Vaccine delivery systems toward lymph nodes
Yingyue Ding, Zhaoting Li, Ana Jaklenec, Quanyin Hu
Advanced Drug Delivery Reviews. 2021; : 113914
[Pubmed] | [DOI]
85 Biomaterials and nanomaterials for sustained release vaccine delivery
Michael A. Luzuriaga, Arezoo Shahrivarkevishahi, Fabian C. Herbert, Yalini H. Wijesundara, Jeremiah J. Gassensmith
WIREs Nanomedicine and Nanobiotechnology. 2021; 13(6)
[Pubmed] | [DOI]
86 Nanoscience versus Viruses: The SARS-CoV-2 Case
Joanna Goscianska, Ralph Freund, Stefan Wuttke
Advanced Functional Materials. 2021; : 2107826
[Pubmed] | [DOI]
87 Enhancement of immunopotentiation using tetanus toxoid-based nanoparticulate dissolvable microneedles
Mansi Waghchaure, Sharayu Govardhane, Pravin Shende
Biomedical Microdevices. 2021; 23(3)
[Pubmed] | [DOI]
88 Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era
Patricia K. Coyle, Anne Gocke, Megan Vignos, Scott D. Newsome
Advances in Therapy. 2021; 38(7): 3550
[Pubmed] | [DOI]
89 COVID-19 and Multiple Sclerosis: Predisposition and Precautions in Treatment
Shaghayegh Sadeghmousavi, Nima Rezaei
SN Comprehensive Clinical Medicine. 2020; 2(10): 1802
[Pubmed] | [DOI]
90 Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert Opinion
Peter Yamoah, Thelma Mpoku Alalbila, Varsha Bangalee, Frasia Oosthuizen
Therapeutic Innovation & Regulatory Science. 2020; 54(6): 1359
[Pubmed] | [DOI]
91 Stimuli-Responsive Biomaterials for Vaccines and Immunotherapeutic Applications
Noah Pacifici, Amir Bolandparvaz, Jamal S. Lewis
Advanced Therapeutics. 2020; 3(11): 2000129
[Pubmed] | [DOI]
92 Incorporation of a Novel CD4+ Helper Epitope Identified from Aquifex aeolicus Enhances Humoral Responses Induced by DNA and Protein Vaccinations
Ziyang Xu, Neethu Chokkalingam, Edgar Tello-Ruiz, Susanne Walker, Daniel W. Kulp, David B. Weiner
iScience. 2020; 23(8): 101399
[Pubmed] | [DOI]
93 COVID-19 Vaccines: A Race Against Time in the Middle of Death and Devastation!
Mohammad S. Khuroo, Mohammad Khuroo, Mehnaaz S. Khuroo, Ahmad A. Sofi, Naira S. Khuroo
Journal of Clinical and Experimental Hepatology. 2020; 10(6): 610
[Pubmed] | [DOI]
94 Lymphatic targeting by albumin-hitchhiking: Applications and optimisation
Mohammad Abdallah, Olivia O. Müllertz, Ian K. Styles, Alexander Mörsdorf, John F. Quinn, Michael R. Whittaker, Natalie L. Trevaskis
Journal of Controlled Release. 2020; 327: 117
[Pubmed] | [DOI]
95 Effects of MS disease-modifying therapies on responses to vaccinations: A review.
John Robert Ciotti, Manouela V. Valtcheva, Anne Haney Cross
Multiple Sclerosis and Related Disorders. 2020; 45: 102439
[Pubmed] | [DOI]
96 Fabrication and Characterization of Tumor Nano-Lysate as a Preventative Vaccine for Breast Cancer
Jenna A. Dombroski, Nidhi Jyotsana, Davis W. Crews, Zhenjiang Zhang, Michael R. King
Langmuir. 2020; 36(23): 6531
[Pubmed] | [DOI]
97 Convalescent plasma therapy: a promising coronavirus disease 2019 treatment strategy
Ravikant Piyush, Keshav Rajarshi, Rajni Khan, Shashikant Ray
Open Biology. 2020; 10(9): 200174
[Pubmed] | [DOI]
98 A COVID-19 vaccine—dare to dream
Alison Phillis
British Journal of Community Nursing. 2020; 25(12): 2
[Pubmed] | [DOI]
99 Vi-Vaccinations Induce Heterogeneous Plasma Cell Responses That Associate With Protection From Typhoid Fever
Deborah L. Cross, Marije K. Verheul, Michael D. Leipold, Gerlinde Obermoser, Celina Jin, Elizabeth Jones, Joshua S. Starr, Irina Mohorianu, Christoph J. Blohmke, Holden T. Maecker, Giorgio Napolitani, Jennifer Hill, Andrew J. Pollard
Frontiers in Immunology. 2020; 11
[Pubmed] | [DOI]
100 Emerging Concepts and Technologies in Vaccine Development
Morgan Brisse, Sophia M. Vrba, Natalie Kirk, Yuying Liang, Hinh Ly
Frontiers in Immunology. 2020; 11
[Pubmed] | [DOI]
101 Designing the Next Generation of Vaccines: Relevance for Future Pandemics
Jorge Domínguez-Andrés, Reinout van Crevel, Maziar Divangahi, Mihai G. Netea, Vinayaka R. Prasad
mBio. 2020; 11(6)
[Pubmed] | [DOI]
102 Toll-like receptors as a therapeutic target in cancer, infections and inflammatory diseases
Lizdany Flórez-Álvarez, Lanie Ruiz-Perez, Natalia Taborda, Juan C Hernandez
Immunotherapy. 2020; 12(5): 311
[Pubmed] | [DOI]

Convalescent Plasma Therapy for Management of COVID-19: Perspectives and Deployment in the Current Global Pandemic

Nandeeta Samad, Temitayo Eniola Sodunke, Hasan Al Banna, Ashmita Sapkota, Aneeka Nawar Fatema, Katia Iskandar, Dilshad Jahan, Timothy Craig Hardcastle, Tanzina Nusrat, Tajkera Sultana Chowdhury, Mainul Haque
Risk Management and Healthcare Policy. 2020; Volume 13: 2707
[Pubmed] | [DOI]
104 Herd immunization with childhood vaccination may provide protection against COVID-19
Yongqiang Yu
Acta Microbiologica et Immunologica Hungarica. 2020; 67(3): 198
[Pubmed] | [DOI]
105 Antimicrobial Resistance: A Tale of Nasty Enemies and Powerful Weapons
Fabiola Vacca, Dario Cardamone, Marco Troisi, Claudia Sala, Rino Rappuoli
Frontiers for Young Minds. 2020; 8
[Pubmed] | [DOI]
106 Perspectives in Peptide-Based Vaccination Strategies for Syndrome Coronavirus 2 Pandemic
Concetta Di Natale, Sara La Manna, Ilaria De Benedictis, Paola Brandi, Daniela Marasco
Frontiers in Pharmacology. 2020; 11
[Pubmed] | [DOI]
107 Vaccination in Atherosclerosis
Felix Sebastian Nettersheim, Lauren De Vore, Holger Winkels
Cells. 2020; 9(12): 2560
[Pubmed] | [DOI]
108 Narrative Review on Health-EDRM Primary Prevention Measures for Vector-Borne Diseases
Emily Chan, Tiffany Sham, Tayyab Shahzada, Caroline Dubois, Zhe Huang, Sida Liu, Kevin Hung, Shelly Tse, Kin Kwok, Pui-Hong Chung, Ryoma Kayano, Rajib Shaw
International Journal of Environmental Research and Public Health. 2020; 17(16): 5981
[Pubmed] | [DOI]
109 Clinician's Perspective on the Use of Hepatitis A Vaccine in Indian Children
Rishi Jain, Chetan Trivedi, Sanjay Marathe, Nishchal Bhat, Archana Karadkhele, Gaurav Puppalwar
Pediatric Infectious Disease. 2020; 1(4): 148
[Pubmed] | [DOI]
110 Alterations in the Human Plasma Lipidome in Response to Tularemia Vaccination
Kristal M. Maner-Smith, Johannes B. Goll, Manoj Khadka, Travis L. Jensen, Jennifer K. Colucci, Casey E. Gelber, Carolyn J. Albert, Steven E. Bosinger, Jacob D. Franke, Muktha Natrajan, Nadine Rouphael, Robert A. Johnson, Patrick Sanz, Evan J. Anderson, Daniel F. Hoft, Mark J. Mulligan, David A. Ford, Eric A. Ortlund
Vaccines. 2020; 8(3): 414
[Pubmed] | [DOI]
111 Immune Response to Vaccination in Patients with Psoriasis Treated with Systemic Therapies
Andrea Chiricozzi, Paolo Gisondi, Francesco Bellinato, Giampiero Girolomoni
Vaccines. 2020; 8(4): 769
[Pubmed] | [DOI]
112 High antibody titres induced by protein subunit vaccines using Mycobacterium ulcerans antigens Hsp18 and MUL_3720 with a TLR-2 agonist fail to protect against Buruli ulcer in mice
Kirstie M. Mangas, Nicholas J. Tobias, Estelle Marion, Jérémie Babonneau, Laurent Marsollier, Jessica L. Porter, Sacha J. Pidot, Chinn Yi Wong, David C. Jackson, Brendon Y. Chua, Timothy P. Stinear
PeerJ. 2020; 8: e9659
[Pubmed] | [DOI]
113 Impact of Microbiota: A Paradigm for Evolving Herd Immunity against Viral Diseases
Asha Shelly, Priya Gupta, Rahul Ahuja, Sudeepa Srichandan, Jairam Meena, Tanmay Majumdar
Viruses. 2020; 12(10): 1150
[Pubmed] | [DOI]
114 In-silico structural modeling and epitope prediction of highly conserved Plasmodium falciparum protein AMR1
Bijara Devi Sanasam, Sanjeev Kumar
Molecular Immunology. 2019; 116: 131
[Pubmed] | [DOI]
115 Current trends in targeted therapy for drug-resistant infections
Leila Rahbarnia, Safar Farajnia, Behrooz Naghili, Vahideh Ahmadzadeh, Kamal Veisi, Roghayyeh Baghban, Sayna Toraby
Applied Microbiology and Biotechnology. 2019; 103(20): 8301
[Pubmed] | [DOI]
116 Lectins as mitosis stimulating factors: Briefly reviewed
Elba V.M.M. Carvalho, Weslley F. Oliveira, Luana C.B.B. Coelho, Maria T.S. Correia
Life Sciences. 2018; 207: 152
[Pubmed] | [DOI]
117 Measuring autophagy level along with vaccine reactive IFN-?+CD4+ Th1 cells may be a promising approach to understand effi cacy of anti TB vaccine(s)
Parkash Om
Journal of Vaccines and Immunology. 2018; : 001
[Pubmed] | [DOI]
118 Effects of different cytokines on immune responses of rainbow trout in a virus DNA vaccination model
Yongsheng Cao, Qiya Zhang, Liming Xu, Shaowu Li, Di Wang, Jingzhuang Zhao, Hongbai Liu, Jian Feng, Tongyan Lu
Oncotarget. 2017; 8(68): 112222
[Pubmed] | [DOI]
119 The ongoing evolution of antibody-based treatments for Ebola virus infection
Emelissa J Mendoza, Trina Racine, Gary P Kobinger
Immunotherapy. 2017; 9(5): 435
[Pubmed] | [DOI]
120 Vaccinations in children on immunosuppressive medications for renal disease
Sushmita Banerjee, Pathum Vindana Dissanayake, Asiri Samantha Abeyagunawardena
Pediatric Nephrology. 2016; 31(9): 1437
[Pubmed] | [DOI]
121 Lentiviral Protein Transfer Vectors Are an Efficient Vaccine Platform and Induce a Strong Antigen-Specific Cytotoxic T Cell Response
Katharina M. Uhlig, Stefan Schülke, Vivian A. M. Scheuplein, Anna H. Malczyk, Johannes Reusch, Stefanie Kugelmann, Anke Muth, Vivian Koch, Stefan Hutzler, Bianca S. Bodmer, Axel Schambach, Christian J. Buchholz, Zoe Waibler, Stephan Scheurer, Michael D. Mühlebach, F. Kirchhoff
Journal of Virology. 2015; 89(17): 9044
[Pubmed] | [DOI]
122 Scrutinizing MHC-I Binding Peptides and Their Limits of Variation
Koch, C.P. and Perna, A.M. and Pillong, M. and Todoroff, N.K. and Wrede, P. and Folkers, G. and Hiss, J.A. and Schneider, G.
PLoS Computational Biology. 2013; 9(6)
123 Immunization update: A 2011 retrospective on product changes and new recommendations
Phillips, K. and Alves, V.
Formulary. 2012; 47(2): 58-74


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Email Alert *
    Add to My List *
* Registration required (free)  

    Components of th...
    Types of Immuniz...
    Stimulation of I...
    Current/Under De...

 Article Access Statistics
    PDF Downloaded3555    
    Comments [Add]    
    Cited by others 123    

Recommend this journal

Sitemap | What's New | Feedback | Copyright and Disclaimer | Privacy Notice | Contact Us
© 2008 Journal of Global Infectious Diseases | Published by Wolters Kluwer - Medknow
Online since 10th December, 2008